Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667606 | 0.94 | ALDH1A1 (0.52) | ALDH1A1CYP2C9CYP2C19LMNATP53 | |
| SCHEMBL22452066 | 0.92 | PLA2G4A (0.42) | ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL12548642 | 0.89 | PLA2G4A (0.54) | ALDH1A1CYP2C9CYP2C19LMNAMEN1 | |
| SCHEMBL17368813 | 0.86 | PLA2G4A (0.49) | LMNA | |
| SCHEMBL17368809 | 0.83 | PLA2G4A (0.61) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL22452061 | 0.82 | PLA2G4A (0.46) | MAPT | |
| SCHEMBL1669773 | 0.80 | PLA2G4A (0.56) | ALDH1A1CYP2C9CYP2C19LMNAMEN1 | |
| SCHEMBL1667568 | 0.79 | PLA2G4A (0.56) | MAPT | |
| SCHEMBL15522833 | 0.78 | LMNA (0.54) | ALDH1A1CYP2C9CYP2C19LMNATP53 | |
| SCHEMBL18388146 | 0.77 | MGLL (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| US-20220363659-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2022-11-17 | — | — | US | disclosed |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| US-10259801-B2 | Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2019-04-16 | — | — | US | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| US-20180105507-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2018-04-19 | — | — | US | disclosed |
| US-20180105507-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2018-04-19 | — | — | US | disclosed |
| US-9597318-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2017-03-21 | — | — | US | disclosed |
| US-9597318-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2017-03-21 | — | — | US | disclosed |
| US-20150376161-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2015-12-31 | — | — | US | disclosed |
| US-20150376161-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2015-12-31 | — | — | US | disclosed |
| EP-2482815-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | Avexxin AS (NO) | 2012-08-08 | — | — | EP | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136879-A1 | COMPOUND | CBR1, CBR3, CCR1 | ALDH1A1 1315/4885CYP2C9 433/4885CYP2C19 888/4885 |
| US-20150376161-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | FOXO1, FOXO3, BCOR | ALDH1A1 1640/4885CYP2C9 1246/4885CYP2C19 2434/4885 |
| US-20180105507-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | FOXO1, FOXO3, BCOR | ALDH1A1 1640/4885CYP2C9 1246/4885CYP2C19 2434/4885 |
| US-10259801-B2 | Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds | OXER1, CCL2, IL6 | ALDH1A1 806/4885CYP2C9 495/4885CYP2C19 1466/4885 |
| US-20220363659-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | OXER1, CASP1, IL6 | ALDH1A1 1190/4885CYP2C9 383/4885CYP2C19 968/4885 |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | CASP1, IL1B, OXER1 | ALDH1A1 1433/4885CYP2C9 296/4885CYP2C19 905/4885 |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | CX3CR1, LTC4S, CBR1 | ALDH1A1 1588/4885CYP2C9 1269/4885CYP2C19 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.